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Most clinicians would like to be able to accurately estimate
the risk of adverse outcomes, especially if this information
could guide management or treatment decisions to lower the
risk for an individual. In the case of atrial ﬁbrillation (AF),
the most common cardiac arrhythmia, more accurate
prediction of its most feared and disabling complica-
tiondstrokedremains a major focus (1,2). This issue is
pertinent as AF is increasing in prevalence and will affect 1
in 4 men and 1 in 6 women during their lifetime (3–8).
Hospitalization for AF is also increasing, with >360,000
admissions annually in the United States for a ﬁrst AF
episode and >2 million admissions for any listing of AF
(9–12). AF causes 15% of all strokes and is also associated
with a 50% increase in mortality for men and a near
doubling of mortality for women compared with matched
subjects without AF (12–15).See page 2274Risk scores for predicting stroke in the setting of AF have
generally been based on clinical variables that are readily
available for most individuals (1,16,17). The CHADS2
score was derived and ﬁrst validated in 2001 and is based
on a history of congestive heart failure, hypertension, age
75 years and older, diabetes, and previous stroke (16). It is
a simple and widely validated risk score that is endorsed by
many guidelines, which more recently have advocated anti-
coagulation for a CHADS2 score 1, based on demon-
stration of beneﬁt from anticoagulation in this context
(16,18,19). As with any simple score, the CHADS2 score
has limitations, including that it takes no account of the
independent risk of stroke conferred by age older than
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stroke and provides extra weighting for age older than
75 years (17). As a consequence, it appears to discriminate
very low risk more accurately than CHADS2 score. Some
guidelines have therefore moved toward recommending the
CHA2DS2VASc score to guide decision making about
anticoagulation (20).
Despite their utility and widespread application to deﬁne
thresholds of stroke risk and to guide anticoagulation for
AF, clinical risk scores provide relatively modest overall
performance as predictors of stroke (1). When assessed by
receiver-operating characteristic analysis, the area under the
curve (AUC) for prediction of the risk of stroke by a clinical
score is generally 0.6 at best, where an AUC of 1.0 would
represent perfect discrimination of events and an AUC of
0.5 is no better than chance for a dichotomous outcome.
The strength of clinical risk scores is that low risk values
(CHADS2 score of 0, CHA2DS2VASc score of 0 to 1)
provide very good sensitivity and negative predictive value
for stroke, which is helpful for deﬁning thresholds for
anticoagulation, but at the cost of poor speciﬁcity and overall
accuracy (21). As a result, risk scores provide weak
discrimination of stroke risk for some individuals, particu-
larly those with intermediate or high scores (1).
Clinical risk scores can potentially be reﬁned by consid-
ering additional indices (1). A range of biomarkers that
reﬂect pathophysiological processes relevant to AF and
stroke also provide independent risk prediction when added
to clinical risk scores (2). These include markers of throm-
bosis (von Willebrand factor, D-dimer), renal function
(creatinine clearance, proteinuria), myocardial necrosis
(troponins), and the natriuretic peptides (N-terminal pro–
B-type natriuretic peptide [NT-proBNP], BNP) (1,2). The
natriuretic peptides, which are powerful markers of risk in
the setting of heart failure and acute coronary syndromes, are
potentially helpful markers in the setting of AF (22).
Secreted from cardiomyocytes, BNP and NT-proBNP levels
in plasma reﬂect left ventricular size, function, and ﬁlling
pressures, but also renal function, age, and sex, all of which
may modify stroke risk in AF (22). Levels of BNP/
NT-proBNP are also higher in subjects with AF than in
matched subjects in sinus rhythm, and levels fall after car-
dioversion, presumably reﬂecting changes in atrial function
and pressure (2,23). BNP or NT-proBNP can be easily
measured using validated assays that are widely available,
which makes them appealing candidates for adjunctive risk
markers (22).
In this issue of the Journal, Hijazi et al. (24) provide some
important insights into the value of NT-proBNP measure-
ments for risk prediction in the setting of AF (24). Their
statistically powerful dataset based on a large cohort of
14,892 patients with at least 1 risk factor for stroke and
enrolled in the ARISTOTLE trial provides deﬁnitive esti-
mates of the incremental value of NT-proBNP levels over
clinical risk scores alone for the prediction of adverse events.
It is important to note that all participants in the
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2286ARISTOTLE trial were receiving anticoagulation, either
apixaban or warfarin, according to a randomization schedule.
In their report, NT-proBNP levels were higher in subjects
with persistent or permanent AF compared with paroxysmal
AF. There was an increased risk of stroke/systemic embo-
lism (SE) or of cardiac death with increasing quartiles of
NT-proBNP, with an increase in hazard ratios of at least 2.3
times for these events for patients in the highest quartile
compared with the lowest quartile. Notably, patients in the
lowest quartile of NT-proBNP levels had very low stroke/
SE rates (1%) regardless of CHA2DS2VASc score.
Clinical risk scores were modest predictors of stroke/SE
and of important events including death or other vascular
events. NT-proBNP levels signiﬁcantly improved the
prediction of all events compared with risk scores alone.
Despite this, overall discrimination remained relatively weak,
with AUC improved by NT-proBNP from 0.626 (for the
CHA2DS2VASc score alone) to 0.646 for prediction of
stroke/SE. There was a more impressive increase in AUC
from 0.59 to 0.69 with NT-proBNP for the prediction of
cardiac deaths. The latter is consistent with NT-proBNP’s
predictive power for cardiac or all-cause mortality in other
settings including heart failure or acute coronary syndromes
(22). Consideration of NT-proBNP levels led to more
accurate classiﬁcation of risk. NT-proBNP level more
accurately classiﬁed patients destined to experience stroke/
SE and more accurately excluded patients who later died
during follow-up. Importantly, there was no interactionTable 1
NT-proBNP and Risk Prediction in Atrial
Insights From the ARISTOTLE and RE-LY
No. of participants
CHADS2 score
1
2
3
NT-proBNP levels
Event rates
Stroke/systemic embolism
Death
Major bleeding
Hazards ratio for major events (NT-proBNP, Q4 vs. Q1)
Stroke
Death
Major bleeding
Added value for stroke/systemic embolism
prediction (area under the curve)
CHA2DS2VASc
CHA2DS2VASc þ NT-proBNP
Added value for composite EPy
prediction (area under the curve)
CHA2DS2VASc
CHA2DS2VASc þ NT-proBNP
Values are n (%), unless indicated otherwise. *p < 0.001. yComposite E
myocardial infarction, and cardiac death, and in the RE-LY, it was stroke,
vascular death. Adapted from Hijazi et al. (24,25).
CI ¼ conﬁdence interval; EP ¼ endpoint; NT-proBNP ¼ N-terminal pro–B-between NT-proBNP level and the treatment effect of
apixaban versus warfarin, nor was there any interaction
between NT-proBNP and major bleeding risk.
The RE-LY study investigators also recently reported
ﬁndings from a similar analysis (25). They measured NT-
proBNP levels in 6,189 participants in the RE-LY study.
Although conﬁdence intervals are wider in the RE-LY study
analyses, reﬂecting the smaller population compared with
that of the ARISTOTLE substudy, the ﬁndings are
remarkably concordant between the 2 studies with respect to
NT-proBNP levels, event rates, the hazards ratios for
subjects in the highest quartile of NT-proBNP, and the
increment in AUC for the prediction of stroke or adverse
clinical outcomes when NT-proBNP was added to clinical
risk scores (Table 1). Taken together these studies provide
a clear picture of the potential value of NT-proBNP in this
setting. It is unlikely that further data from this setting will
alter the insights that these studies provide due to their size
and statistical power.
Howdo the ﬁndings of this study alter our evaluation of risk
and management of AF? First, it is important to note some
limitations to the data. As the authors point out, all patients
were receiving anticoagulation; therefore, it is not possible to
translate these ﬁndings to guide decision making for patients
yet to commence anticoagulation. Although it is possible that
NT-proBNP level might provide valuable risk stratiﬁcation in
this context, clear validation of NT-proBNP level as a marker
of stroke risk in the setting of no anticoagulation, or beforeFibrillation:
Trials
ARISTOTLE RE-LY
14,892 6,189
5,057 (34) 2,025 (33)
5,367 (36) 2,197 (35)
4,468 (30) 1,967 (32)
714 (95% CI: 363–1,250) 801 (95%: 387–1,403)
1.4%/yr 1.3%/yr
3.69%/yr 3.3%/yr
2.61%/yr 2.45%/yr
2.35* (1.62–3.40) 2.30* (1.41–4.07)
2.25* (1.80–2.81) 6.73* (3.95–11.49)
1.07 (0.82–1.40) 1.28 (0.87–1.88)
0.62 0.618
0.646* 0.633
0.598 0.612
0.66* 0.668*
P in the ARISTOTLE trial was ischemic stroke, systemic embolism,
systemic embolism, pulmonary embolism, myocardial infarction, and
type natriuretic peptide.
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2287anticoagulation being commenced, would be required
before guidelines could endorse NT-proBNP level for this
application. For now, the established clinical risk scores
remain the best validated approach to guiding decisions about
when to commence anticoagulation. Another limitation of the
current data is that ﬁndings of the clinical trial settingmay not
always be replicated in real-world patient populations. Given
the large size of the current study, this seems less likely.
However, it is important to note that the very elderly, who
have a higher AF prevalence and stroke risk, are not repre-
sented in the study.
However, the ﬁndings from this large substudy of the
ARISTOTLE trial and also the smaller substudy of the
RE-LY study indicate that among subjects fully anti-
coagulated for AF, a single measurement of NT-proBNP
provides powerful prediction of the residual risk of either
stroke/SE or of cardiovascular complications. Subjects who
are receiving anticoagulation for AF and who have low
NT-proBNP levels (<363 ng/l) are at very low risk of stroke/
SE or cardiac death regardless of their CHA2DS2VASc score.
Conversely, if NT-proBNP levels are high (>1,250 ng/l), the
risk of these events is high, even when the CHA2DS2VASc
score is 2. Although guidelines may not endorse routine
measurement of NT-proBNP levels, this information may
have signiﬁcant clinical utility, particularly in patients for
whom there are concerns about major bleeding or other
risks related to anticoagulation (26).
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